Table 2 Clinical description of COPD by gender
From: Clinical characteristics and quality of life in women with COPD: an observational study
Men (n = 183) | Women (n = 247) | p | n (M/W) | |
|---|---|---|---|---|
COPD symptoms (%) | 42.6% | 57.4% | ||
Chronic cough | 75.6 | 78.5 | ||
Chronic sputum | 62 | 64.2 | NS | 182/245 |
Dyspnea MRC stage 0- 1–2 (%) | 73.7 | 72.7 | NS | 179/242 |
Dyspnea MRC stage 3–4 (%) | 26.3 | 27.3 | ||
COPD exacerbation (< 12 months) (%) | 58.2 | 65.7 | NS | 182/245 |
FEV 1 (% predicted) | 46.2 ±14.4 | 52.1 ± 15.9 | < 0.001 | 162/224 |
FEV 1 /FVC post BD | 57.9 ± 13.6 | 58.9 ± 13.1 | NS | 170/231 |
GOLD stage 2 | 42.9% | 54.6% | ||
3 | 39.5% | 37.4% | 0.026 | 119/163 |
4 | 17.6% | 8.0% | ||
Short- acting ß2 -agonists | 40 | 53.1 | 0.010 | 170/226 |
BOD index | 2.9 ±1.6 | 2.6 ±1.6 | NS | 183/247 |
HAD anxiety sub-score (0–21) | 7.1 ± 4.3 | 9.8 ± 4.3 | < 0.001 | 131/177 |
HAD depression sub-score (0–21) | 6.1 ± 4.4 | 6.6 ± 4.6 | NS | 128/177 |
Q- MAT score (0–20) | 9.3 ±6 | 8.7 ±5.9 | NS | 46/93 |